Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

GM-CSF in marrow transplantation

K H Antman1

  • 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

European Journal of Cancer (Oxford, England : 1990)
|January 1, 1993
PubMed
Summary

Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) speeds up bone marrow transplant recovery. This therapy reduces infection risk, antibiotic use, and hospital stays for transplant patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Syngeneic hematopoietic stem cell transplantation for women with metastatic breast cancer.

Bone marrow transplantation·2003
Same author

New biology and therapies in soft tissue sarcomas.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2002
Same author

Overview of the six available randomized trials of high-dose chemotherapy with blood or marrow transplant in breast cancer.

Journal of the National Cancer Institute. Monographs·2002
Same author

Protocol for the examination of specimens from patients with tumors of the peritoneum: a basis for checklists.

Archives of pathology & laboratory medicine·2001
Same author

Introduction: the history of arsenic trioxide in cancer therapy.

The oncologist·2001
Same author

Randomized trials of high dose chemotherapy for breast cancer.

Biochimica et biophysica acta·2001

Area of Science:

  • Hematology
  • Immunology
  • Oncology

Background:

  • Bone marrow transplantation (BMT) is a critical treatment for various diseases.
  • Patients undergoing BMT are highly vulnerable to opportunistic infections during engraftment.
  • Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) supports hematopoietic recovery.

Purpose of the Study:

  • To evaluate the efficacy of rhGM-CSF as an adjunct therapy in bone marrow transplantation.
  • To assess the impact of rhGM-CSF on engraftment time and patient outcomes.

Main Methods:

  • Review of clinical trials involving BMT patients treated with rhGM-CSF.
  • Analysis of key outcomes including duration to re-engraftment, antibiotic use, and hospitalization period.

Main Results:

  • Administration of rhGM-CSF significantly shortened the duration to myeloid re-engraftment.
  • Patients receiving rhGM-CSF experienced fewer antibiotic treatment days.
  • The period of hospitalization was reduced in patients treated with rhGM-CSF.

Conclusions:

  • rhGM-CSF demonstrates significant benefits as an adjunct therapy in bone marrow transplantation.
  • rhGM-CSF effectively accelerates hematopoietic recovery and improves clinical outcomes post-BMT.
  • The use of rhGM-CSF can mitigate complications and reduce healthcare resource utilization in BMT patients.

Related Experiment Videos